TRex Bio (TRXB) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
X4 Pharmaceuticals is the larger company by market cap ($306.3 million vs $297.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRXB | XFOR |
|---|---|---|
| Share price | $10.32 | $3.00 |
| Market cap | $296.95M | $306.34M |
| 1-day change | +6.12% | +1.35% |
| YTD return | — | -25.00% |
| 1-year return | — | -20.00% |
| 5-year return | — | -97.79% |
| P/E ratio (TTM) | — | 5.45 |
| EPS (TTM) | $-2.74 | $0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.50M |
| Revenue growth (YoY) | — | +150.00% |
| Net income (latest FY) | — | $-79.20M |
| Gross margin | — | 11.43% |
| Operating margin | — | -1336.66% |
| Net margin | — | -1218.45% |
| 52-week high | $16.56 | $4.83 |
| 52-week low | $9.06 | $2.43 |
| Distance from 52-week high | -37.71% | -37.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +183.57% | +286.67% |
| Average volume | 156.80K | 877.70K |
| Shares outstanding | 28.79M | 102.11M |
| Employees | 60 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About TRex Bio
TRXB stock →TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
TRXB vs XFOR FAQ
Which is bigger, TRex Bio or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $306.34M compared with $296.95M for TRex Bio (TRXB).
Are TRex Bio and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.